Daptomycin therapy failure in an adolescent with methicillin-resistant staphylococcus aureus bacteremia

Pediatric Infectious Disease Journal

Volumn 28, Issue 5, 2009, Pages 445-447

  Jacobson, Lara M ^a   Milstone, Aaron M ^b   Zenilman, Jonathan ^c   Carroll, Karen C ^b   Arav Boger, Ravit ^b  

^a CMSC 2 124 ^*  (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS BAYVIEW MEDICAL CENTER   (United States)

Author keywords

Daptomycin; MRSA; Nonsusceptible; Resistance; Staphylococcus aureus

Indexed keywords

DAPTOMYCIN; GENTAMICIN; METICILLIN; VANCOMYCIN;

ADOLESCENT; ADOLESCENT DISEASE; ARTICLE; BACTEREMIA; BURN; CASE REPORT; CEREBROSPINAL FLUID CULTURE; DISEASE COURSE; DISEASE EXACERBATION; DRUG EFFICACY; DRUG MONITORING; DRUG WITHDRAWAL; ENDOCARDITIS; HUMAN; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MITRAL VALVE REPLACEMENT; PRIORITY JOURNAL; SEPSIS; STAPHYLOCOCCUS INFECTION; TREATMENT FAILURE;

EID: 67649531477     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e3181927891     Document Type: Article

References (22)

1. Koeth L, DiFranco J. Comparison of daptomycin Etest MICs on Mueller-Hinton, Iso-Sensitest and brain-heart infusion agars with and without calcium supplementation to broth micro-dilution MICs against 20 Staphylococcus auerus isolates. In: 18th European Congress of Clinical Microbiology and Infectious Disease. Barcelona, Spain; 2008.
2. Steinkraus G, White R, Friedrich L. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-sus-ceptible clinical methicillin-resistant Staphylococcus aureus (MRSA) blood isolates from 2001-05. J Antimicrob Chemother. 2007;60:788-794.
3. Fowler VG Jr, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med. 2006;355:653-665.
4. Falagas ME, Giannopoulou KP, Ntziora F, et al. Daptomycin for endocarditis and/or bacteraemia: a systematic review of the experimental and clinical evidence. J Antimicrob Chemother. 2007;60:7-19.
5. Ardura MI, Mejias A, Katz KS, et al. Daptomycin therapy for invasive Gram-positive bacterial infections in children. Pediatr Infect Dis J. 2007; 26:1128-1132.
6. Abdel-Rahman SM, Benziger DP, Jacobs RF, et al. Single-dose pharmacokinetics of daptomycin in children with suspected or proved grampositive infections. Pediatr Infect Dis J. 2008;27:330 -334.
7. Akins RL, Haase MR, Levy EN. Pharmacokinetics of daptomycin in a critically ill adolescent with vancomycin-resistant enterococcal endocarditis. Pharmacotherapy. 2006;26:694-698.
8. Cohen-Wolkowiez M, Smith PB, Benjamin DK Jr, et al. Daptomycin use in infants: report of two cases with peak and trough drug concentrations. J Perinatol. 2008;28:233-234.
9. Mohr JF III, Ostrosky-Zeichner L, Wainright DJ, et al. Pharmacokinetic evaluation of single-dose intravenous daptomycin in patients with thermal burn injury. Antimicrob Agents Chemother. 2008;52:1891-1893.
10. Rose WE, Rybak MJ, Kaatz GW. Evaluation of daptomycin treatment of Staphylococcus aureus bacterial endocarditis: an in vitro and in vivo simulation using historical and current dosing strategies. J Antimicrob Chemother. 2007;60:334-340.
11. Sader HS, Streit JM, Fritsche TR, et al. Antimicrobial activity of daptomy-cin against multidrug-resistant Gram-positive strains collected worldwide. Diagn Microbiol Infect Dis. 2004;50:201-204.
12. Hayden MK, Rezai K, Hayes RA, et al. Development of Daptomycin resistance in vivo in methicillin-resistant Staphylococcus aureus. J Clin Microbiol. 2005;43:5285-5287.
13. Huang YT, Hsiao CH, Liao CH, et al. Bacteremia and infective endocarditis caused by a non-daptomycin-susceptible, vancomycin-intermediate, and methicillin-resistant Staphylococcus aureus strain in Taiwan. J Clin Microbiol. 2008;46:1132-1136.
14. Bennett JW, Murray CK, Holmes RL, et al. Diminished vancomycin and daptomycin susceptibility during prolonged bacteremia with methicillin- resistant Staphylococcus aureus. Diagn Microbiol Infect Dis. 2008;60:437-440.
15. Hirschwerk D, Ginocchio CC, Bythrow M, et al. Diminished susceptibility to daptomycin accompanied by clinical failure in a patient with methicillin-resistant Staphylococcus aureus bacteremia. Infect Control Hosp Epidemiol. 2006;27:315-317.
16. Julian K, Kosowska-Shick K, Whitener C, et al. Characterization of a daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus au-reus strain in a patient with endocarditis. Antimicrob Agents Chemother. 2007;51:3445-3448.
17. Mangili A, Bica I, Snydman DR, et al. Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis. 2005;40: 1058-1060.
18. Mariani PG, Sader HS, Jones RN. Development of decreased susceptibility to daptomycin and vancomycin in a Staphylococcus aureus strain during prolonged therapy. J Antimicrob Chemother. 2006;58:481-483.
19. Marty FM, Yeh WW, Wennersten CB, et al. Emergence of a clinical daptomycin-resistant Staphylococcus aureus isolate during treatment of methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis. J Clin Microbiol. 2006;44:595-597.
20. Sharma M, Riederer K, Chase P, et al. High rate of decreasing daptomycin susceptibility during the treatment of persistent Staphylococcus aureus bacteremia. Eur J Clin Microbiol Infect Dis. 2008;27:433-437.
21. Murthy MH, Olson ME, Wickert RW, et al. Daptomycin non-susceptible meticillin-resistant Staphylococcus aureus USA 300 isolate. J Med Microbiol. 2008;57:1036-1038.
22. Enoch DA, Bygott JM, Daly ML, et al. Daptomycin. J Infect. 2007;55: 205-213.